Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VOLITIONRX LTDVNRX · Entity 8241 | Director | February 26, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VOLITIONRX LTD
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,252,967 |
Reported balance
After 2026-02-26 transaction · row 1
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 178,000 · Balance 1,252,967 F1: On February 26, 2026, the reporting person was awarded 178,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on February 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy The Innes Family Bare Trust 2023 | 1,400,000 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,400,000 F2: These shares of Common Stock are beneficially owned by The Innes Family Bare Trust 2023, which is a separate legal entity, of which the reporting person is the Trustee, for the benefit of his children. |
| Common StockSEC Table I · non-derivative | IndirectBy The Dill Faulkes Educational Trust Limited | 356,000 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 356,000 F3: These shares of Common Stock are beneficially owned by The Dill Faulkes Educational Trust Limited ("DFET"), a UK registered charity. The reporting person serves as a director and trustee of DFET and shares voting and dispositive control over these shares but disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy son | 154,503 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 154,503 |
| Common StockSEC Table I · non-derivative | IndirectBy son | 154,503 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 154,503 |
| Common StockSEC Table I · non-derivative | IndirectBy daughter | 154,504 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 154,504 |
| Common StockSEC Table I · non-derivative | IndirectBy daughter | 154,504 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 154,504 |
Filing footnotes · ownership attribution and instrument terms
F1: On February 26, 2026, the reporting person was awarded 178,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on February 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date.
F2: These shares of Common Stock are beneficially owned by The Innes Family Bare Trust 2023, which is a separate legal entity, of which the reporting person is the Trustee, for the benefit of his children.
F3: These shares of Common Stock are beneficially owned by The Dill Faulkes Educational Trust Limited ("DFET"), a UK registered charity. The reporting person serves as a director and trustee of DFET and shares voting and dispositive control over these shares but disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2022 Filed Apr 8, 2022 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 1,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-002176 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,536,615 F1 · shares: On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 1,640 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 820 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $3.60 | Not disclosed |
DisclosureSEC source: 0001477932-21-009118 · form4.xml · derivative · entry 2 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-04-13 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant). Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $3.60 | Not disclosed |
DisclosureSEC source: 0001477932-21-009118 · form4.xml · derivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2026-04-13 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001477932-21-007865 · form4.xml · derivative · entry 6 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-01-23 F3 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant). F3 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001477932-21-007865 · form4.xml · derivative · entry 5 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-01-23 F3 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant). F3 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001477932-21-007865 · form4.xml · derivative · entry 4 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-03-30 F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant). F2 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001477932-21-007865 · form4.xml · derivative · entry 3 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-03-30 F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant). F2 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001477932-21-007865 · form4.xml · derivative · entry 2 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2026-04-15 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001477932-21-007865 · form4.xml · derivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2022-04-15 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant). Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 20:50 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001078782-21-000677 · primary_doc.xml · derivative · entry 2 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2025-07-23 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant). Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 20:50 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001078782-21-000677 · primary_doc.xml · derivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-07-23 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant). Read SEC document |
| May 17, 2021 Filed May 18, 2021 15:37 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 50,000 | $3.47 | $173,500.00 |
DisclosureSEC source: 0001078782-21-000462 · primary_doc.xml · nonDerivative · entry 2 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,534,975 Read SEC document |
| May 14, 2021 Filed May 18, 2021 15:37 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 100,000 | $3.29 | $329,000.00 |
DisclosureSEC source: 0001078782-21-000462 · primary_doc.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,484,975 Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 14:47 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001078782-20-000635 · primary_doc.xml · derivative · entry 5 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2020-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 14:47 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001078782-20-000635 · primary_doc.xml · derivative · entry 4 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2020-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 14:47 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Exercise / conversionCommon Stock | 15,000 | $3.00 | $45,000.00 |
DisclosureSEC source: 0001078782-20-000635 · primary_doc.xml · nonDerivative · entry 2 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,384,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 14:47 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Exercise / conversionCommon Stock | 15,000 | $2.50 | $37,500.00 |
DisclosureSEC source: 0001078782-20-000635 · primary_doc.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,369,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 21:30 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001078782-20-000270 · primary_doc.xml · derivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-04-13 F1 · derivative.exercise_date: A total of 25,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:44 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Options (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001078782-19-000134 · primary_doc.xml · derivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2025-02-11 F1 · derivative.exercise_date: A total of 25,000 Options were granted on February 11, 2019 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 21:46 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantOption (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001078782-18-001446 · primary_doc.xml · derivative · entry 6 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2021-07-23 F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015 and vested in full at 6 months from the date of grant, and were exercisable for four years from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2021. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 21:46 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerOption (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001078782-18-001446 · primary_doc.xml · derivative · entry 5 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2020-01-23 F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015 and vested in full at 6 months from the date of grant, and were exercisable for four years from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2021. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 21:46 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantOption (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001078782-18-001446 · primary_doc.xml · derivative · entry 4 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2020-08-18 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on August 18, 2014 and vested in two equal installments at 6 months and at 18 months from the date of grant, and were exercisable for four years from the date first exercisable. The "replacement" options are fully-vested and both installments expire on August 18, 2020. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 21:46 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantOption (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001078782-18-001446 · primary_doc.xml · derivative · entry 3 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2020-08-18 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on August 18, 2014 and vested in two equal installments at 6 months and at 18 months from the date of grant, and were exercisable for four years from the date first exercisable. The "replacement" options are fully-vested and both installments expire on August 18, 2020. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 21:46 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerOption (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001078782-18-001446 · primary_doc.xml · derivative · entry 2 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2020-02-18 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on August 18, 2014 and vested in two equal installments at 6 months and at 18 months from the date of grant, and were exercisable for four years from the date first exercisable. The "replacement" options are fully-vested and both installments expire on August 18, 2020. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 21:46 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerOption (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001078782-18-001446 · primary_doc.xml · derivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-02-18 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on August 18, 2014 and vested in two equal installments at 6 months and at 18 months from the date of grant, and were exercisable for four years from the date first exercisable. The "replacement" options are fully-vested and both installments expire on August 18, 2020. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 14:27 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 49,826 | $2.00 | $99,652.00 |
DisclosureSEC source: 0001078782-18-000900 · primary_doc.xml · nonDerivative · entry 4 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354,975 Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 14:27 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 14 | $1.99 | $27.86 |
DisclosureSEC source: 0001078782-18-000900 · primary_doc.xml · nonDerivative · entry 3 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,305,149 Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 14:27 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 7 | $1.97 | $13.79 |
DisclosureSEC source: 0001078782-18-000900 · primary_doc.xml · nonDerivative · entry 2 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,305,135 Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 14:27 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 153 | $1.95 | $298.35 |
DisclosureSEC source: 0001078782-18-000900 · primary_doc.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,305,128 Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 18:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001078782-18-000065 · primary_doc.xml · derivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2024-01-23 F1 · derivative.exercise_date: A total of 20,000 Options were granted on January 23, 2018 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant. Read SEC document |
| April 18, 2017 Filed Apr 19, 2017 21:12 UTC | VOLITIONRX LTD VNRX · Entity 8241 | OtherWarrant (Right to Buy) · Derivative | 1,786 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001078782-17-000520 · primary_doc.xml · derivative · entry 4 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,786 shares Expires 2017-05-10 F2 · derivative.underlying_shares: On April 18, 2017, a bare trust, of which the Reporting Person is the Trustee, exercised a warrant to purchase 1,786 shares of Common Stock of the issuer for $2.60 per share. The warrant was set to expire pursuant to its terms on May 10, 2017. F3 · ownership.nature: The foregoing shares and warrants are held by a bare trust, which is not a separate legal entity, of which Mr. Innes is the Trustee, for the benefit of certain minors. Read SEC document |
| April 18, 2017 Filed Apr 19, 2017 21:12 UTC | VOLITIONRX LTD VNRX · Entity 8241 | OtherWarrant (Right to Buy) · Derivative | 74,821 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001078782-17-000520 · primary_doc.xml · derivative · entry 3 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,821 shares Expires 2017-05-10 F1 · derivative.underlying_shares: On April 18, 2017, the Reporting Person exercised a warrant to purchase 74,821 shares of Common Stock of the issuer for $2.60 per share. The warrant was set to expire pursuant to its terms on May 10, 2017. Read SEC document |
| April 18, 2017 Filed Apr 19, 2017 21:12 UTC | VOLITIONRX LTD VNRX · Entity 8241 | OtherCommon Stock | 1,786 | $2.60 | $4,643.60 |
DisclosureSEC source: 0001078782-17-000520 · primary_doc.xml · nonDerivative · entry 2 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 49,726 F2 · balance_after: On April 18, 2017, a bare trust, of which the Reporting Person is the Trustee, exercised a warrant to purchase 1,786 shares of Common Stock of the issuer for $2.60 per share. The warrant was set to expire pursuant to its terms on May 10, 2017. F3 · ownership.nature: The foregoing shares and warrants are held by a bare trust, which is not a separate legal entity, of which Mr. Innes is the Trustee, for the benefit of certain minors. Read SEC document |
| April 18, 2017 Filed Apr 19, 2017 21:12 UTC | VOLITIONRX LTD VNRX · Entity 8241 | OtherCommon Stock | 74,821 | $2.60 | $194,534.60 |
DisclosureSEC source: 0001078782-17-000520 · primary_doc.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,304,975 F1 · balance_after: On April 18, 2017, the Reporting Person exercised a warrant to purchase 74,821 shares of Common Stock of the issuer for $2.60 per share. The warrant was set to expire pursuant to its terms on May 10, 2017. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 20:20 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001078782-17-000409 · primary_doc.xml · derivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2023-03-30 F1 · derivative.exercise_date: A total of 20,000 Options were granted on March 30, 2017 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant. Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 21:24 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001078782-16-003845 · primary_doc.xml · derivative · entry 3 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2016-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 21:24 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 3,349 | $4.48 | $15,003.52 |
DisclosureSEC source: 0001078782-16-003845 · primary_doc.xml · nonDerivative · entry 2 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,230,154 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation as payment of the exercise price in a cashless exercise. No shares were sold by the Reporting Person or VolitionRx in such cashless exercise transaction. Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 21:24 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Exercise / conversionCommon Stock | 5,000 | $3.00 | $15,000.00 |
DisclosureSEC source: 0001078782-16-003845 · primary_doc.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,233,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.